Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
November, 2026
November 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Mehak Trehan: ASH 2026 Benign Hematology – Ten Abstracts Through an Indian Lens
Mehak Trehan/LinkedIn
Nov 14, 2026, 23:43

Mehak Trehan: ASH 2026 Benign Hematology – Ten Abstracts Through an Indian Lens

Mehak Trehan, Subject Matter Expert at DailyRounds, shared a post on X:

“ASH 2026, Benign Hematology

Beyond the blood count: what outcomes should we be watching?

Ten abstracts through an Indian lens.

Fewer bleeds. Fewer transfusions. Preserved organs. Less treatment burden. These are the outcomes I’m watching.

1. Iron deficiency without anemia – 726

In 200 pregnant women in a US cohort, 64% had iron deficiency without anemia. An observational signal to study ferritin, fatigue and treatment benefit in Indian pregnancy care.

2. Bleeding ITP: IVIORDEX – 25

Day-5 response: 72.1% with dexamethasone vs 84.4% with IVIG or prednisone; non-inferiority was not met. Rescue needs matter when IVIG is expensive. Life-threatening bleeding was excluded.

3. Aplastic anemia: RACE follow-up – 350

Five-year DFS: 43% vs 30% with horse ATG or CsA plus eltrombopag vs without; no significant OS difference. Durability, relapse and clonal evolution matter alongside early response.

4. AIHA: the steroid burden– 4626

TRUTH, a 510-patient UK audit, recorded infections requiring admission in 20.7% during steroid treatment. Cumulative exposure, bone health and infection prevention deserve an audit here too.

5. Thalassemia: an Indian access model – 305

An analysis of 1,004 transplants under Thalassemia Bal Sewa Yojana reports estimated 2-year OS of 91%. Funding and donor access belong in the discussion about making curative therapy attainable.

6. Sickle cell: hydroxyurea – 4706

ADAPT: transfusion rates fell from 2.3 to 0.9 units/person-year in 106 Ugandan children. Before-and-after data, with an endpoint worth auditing in Indian programmes.

7. Sickle cell: SCD-CARRE – 3

In high-risk adults, monthly automated exchange reduced the unplanned-care/death composite (rate ratio 0.66), without a demonstrated survival benefit. Blood supply and alloimmunisation remain central.

8. Hemophilia in women– 601

FVIII 40% or more did not exclude abnormal bleeding. Bleeding history and genotype add information that a reassuring factor level can miss: relevant to menstrual and procedural care.

9. TTP: recovery beyond platelets– 181
24% of scans during ADAMTS13 remission were abnormal in a selected MRI cohort. Long-term brain health deserves study; these data do not establish universal MRI screening.

10. Thrombosis: ASTER – 187

Cancer-associated VTE recurrence: 7.7% with abelacimab vs 2.7% with apixaban, despite less bleeding; the trial stopped early. Safety and antithrombotic efficacy must be read together.

For India, I’m watching both clinical benefit and the systems needed to deliver it.”

Mehak Trehan

Stay updated with Hemostasis Today.

AA Abelacimab ADAMTS13 ADAPT AIHA anemia Apixaban aplastic anemia ASH 2026 ATG Bal Sewa Yojana benign hematology Blood CsA Dexamethasone Eltrombopag Ferritin FVIII Health Hematology Hemostasis Hemostasis News Hemostasis Today Hydroxyurea India Iron Deficiency Without Anemia Iron-Deficiency ITP IVIG Medicine Mehak Trehan Prednisone SCD-CARRE Sickle Cell Thalassemia UK US VTE
NewsFeed